BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17101065)

  • 41. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
    Demetri GD
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neoadjuvant and adjuvant therapy with imatinib for locally advanced gastrointestinal stromal tumors in eastern Indian patients.
    Ashraf M; Jha J; Choudhry A; Aggarwal B; Nayak S; Chakraborty J; Majumder S; Biswas J
    Asian Pac J Cancer Prev; 2011; 12(8):2059-64. PubMed ID: 22292651
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665.
    Eisenberg BL; Harris J; Blanke CD; Demetri GD; Heinrich MC; Watson JC; Hoffman JP; Okuno S; Kane JM; von Mehren M
    J Surg Oncol; 2009 Jan; 99(1):42-7. PubMed ID: 18942073
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Surgical resection of gastrointestinal stromal tumor after treatment with imatinib: clinical case].
    Baldo S; Rivoire M; Sobrero A; Comandini D; Civalleri D; Stella M; Quaglia F; Santoni R; Malerba M; Mariani F; DeCian F
    Suppl Tumori; 2005; 4(3):S97. PubMed ID: 16437930
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib.
    Chang SC; Liao CH; Wang SY; Tsai CY; Chiang KC; Cheng CT; Yeh TS; Chen YY; Ma MC; Liu CT; Yeh CN
    Medicine (Baltimore); 2015 Jun; 94(24):e1014. PubMed ID: 26091448
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Two cases of surgical resection of rectal gastrointestinal stromal tumor after neoadjuvant therapy with imatinib mesylate].
    Nakashima S; Fujita Y; Matsuo H; Ariyoshi Y; Fukuda K; Fujiyama J; Masuyama M
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):1932-4. PubMed ID: 23267934
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives.
    Apice G; Milano A; Bruni GS; Iaffaioli RV; Caponigro F
    Rev Recent Clin Trials; 2006 Jan; 1(1):35-42. PubMed ID: 18393778
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Imatinib in the GIST therapy: ten years later].
    Lopez M
    Clin Ter; 2011; 162(6):563-73. PubMed ID: 22262331
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gastrointestinal stromal tumor: 5 years later.
    van der Zwan SM; DeMatteo RP
    Cancer; 2005 Nov; 104(9):1781-8. PubMed ID: 16136600
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era.
    Wu PC; Langerman A; Ryan CW; Hart J; Swiger S; Posner MC
    Surgery; 2003 Oct; 134(4):656-65; discussion 665-6. PubMed ID: 14605627
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Developments in targeted therapy of advanced gastrointestinal stromal tumors.
    Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA
    Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Imaging of gastrointestinal stromal tumors before and after imatinib mesylate therapy.
    Shankar S; Dundamadappa SK; Karam AR; Stay RM; van Sonnenberg E
    Acta Radiol; 2009 Oct; 50(8):837-44. PubMed ID: 19735005
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [A case of a giant rectal gastrointestinal stromal tumor radically resectable after treatment with neoadjuvant imatinib mesylate].
    Sassa M; Kobayashi Y; Sugeno H; Iwadate M; Suzuki S; Endo Y; Nakamura I; Ohki S; Takenoshita S
    Gan To Kagaku Ryoho; 2013 Jul; 40(7):937-41. PubMed ID: 23863741
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pathologic complete response with neoadjuvant imatinib for locally advanced pelvic GIST.
    de Azevedo CR; Paiva TF; Rossi BM; Guimarães GC; de Souza Begnami MD; Oliveira TB; Barros E Silva MJ; Fanelli MF; de Mello CA
    Int J Clin Oncol; 2011 Jun; 16(3):279-83. PubMed ID: 20922448
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Surgical treatment of locally advanced, non-metastatic, gastrointestinal stromal tumours after treatment with imatinib.
    Tielen R; Verhoef C; van Coevorden F; Gelderblom H; Sleijfer S; Hartgrink HH; Bonenkamp JJ; van der Graaf WT; de Wilt JH
    Eur J Surg Oncol; 2013 Feb; 39(2):150-5. PubMed ID: 23084087
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An unusual and potentially misleading phenotypic change in a primary gastrointestinal stromal tumour (GIST) under imatinib mesylate therapy.
    Vassos N; Agaimy A; Schlabrakowski A; Hohenberger W; Schneider-Stock R; Croner RS
    Virchows Arch; 2011 Mar; 458(3):363-9. PubMed ID: 21191613
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Curative resection of an extra-gastrointestinal stromal tumor locally advanced and fistulizing in the small intestine after treatment with imatinib: report of a case].
    Bouassria A; Mouaqit O; Benjelloun E; Elbouhaddouti H; Ousadden A; Mazaz K; Taleb KA
    Pan Afr Med J; 2014; 17():247. PubMed ID: 25309647
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of surgical resection following imatinib treatment in patients with recurrent or metastatic gastrointestinal stromal tumors: results of propensity score analyses.
    Park SJ; Ryu MH; Ryoo BY; Park YS; Sohn BS; Kim HJ; Kim CW; Kim KH; Yu CS; Yook JH; Kim BS; Kang YK
    Ann Surg Oncol; 2014 Dec; 21(13):4211-7. PubMed ID: 24980089
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current management of gastrointestinal stromal tumors--a comprehensive review.
    Lai EC; Lau SH; Lau WY
    Int J Surg; 2012; 10(7):334-40. PubMed ID: 22633986
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.
    Rutkowski P; Gronchi A; Hohenberger P; Bonvalot S; Schöffski P; Bauer S; Fumagalli E; Nyckowski P; Nguyen BP; Kerst JM; Fiore M; Bylina E; Hoiczyk M; Cats A; Casali PG; Le Cesne A; Treckmann J; Stoeckle E; de Wilt JH; Sleijfer S; Tielen R; van der Graaf W; Verhoef C; van Coevorden F
    Ann Surg Oncol; 2013 Sep; 20(9):2937-43. PubMed ID: 23760587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.